Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-09
2010-06-01
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S016000
Reexamination Certificate
active
07727998
ABSTRACT:
The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]:[wherein R1is hydrogen, hydroxyl, lower alkyl, or the like; R2, R3a, R3b, R4a, R4b, R5a, R5band R6each stands for hydrogen, halogen, or the like; W1and W2each independently stands for —O—, —CH2—, or the like; Y1, Y2, Y3and Y4stand for —CH—, —CF—, —N—, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.
REFERENCES:
patent: 6472394 (2002-10-01), McKittrick et al.
patent: 6569861 (2003-05-01), Bakthavatchalam et al.
patent: 6664273 (2003-12-01), Burnett et al.
patent: 6720324 (2004-04-01), Marzabadi et al.
patent: 6727264 (2004-04-01), Marzabadi et al.
patent: 6818772 (2004-11-01), Kym et al.
patent: 6887889 (2005-05-01), Hobbs et al.
patent: 6900329 (2005-05-01), Clader et al.
patent: 6906075 (2005-06-01), DeSimone et al.
patent: 6930185 (2005-08-01), Ishihara et al.
patent: 7335665 (2008-02-01), Marzabadi et al.
patent: 2002/0072604 (2002-06-01), Carpino et al.
patent: 2003/0023085 (2003-01-01), Chen et al.
patent: 2003/0105094 (2003-06-01), Clader et al.
patent: 2003/0144261 (2003-07-01), Palani et al.
patent: 2003/0158177 (2003-08-01), Ishihara et al.
patent: 2003/0212070 (2003-11-01), Schwink et al.
patent: 2004/0024002 (2004-02-01), Burnett et al.
patent: 2004/0063700 (2004-04-01), Cheng et al.
patent: 2004/0106645 (2004-06-01), Blackburn et al.
patent: 2004/0220404 (2004-11-01), Carpenter et al.
patent: 2005/0049269 (2005-03-01), Wu et al.
patent: 2005/0182068 (2005-08-01), Hutchison et al.
patent: 2006/0173027 (2006-08-01), Marzabadi et al.
patent: 1219294 (2002-07-01), None
patent: 1447402 (2004-08-01), None
patent: 11-507344 (1993-01-01), None
patent: 2001 226269 (2001-08-01), None
patent: 2002 003370 (2002-01-01), None
patent: 2002 371059 (2002-12-01), None
patent: WO 96/40136 (1996-12-01), None
patent: WO 01/21169 (2001-03-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 01/82925 (2001-08-01), None
patent: WO 02/00654 (2002-01-01), None
patent: WO 02/02744 (2002-01-01), None
patent: WO 02/06245 (2002-01-01), None
patent: WO 02/076929 (2002-10-01), None
patent: WO 02/088089 (2002-11-01), None
patent: WO 03/028641 (2003-04-01), None
patent: WO 03/045313 (2003-06-01), None
patent: WO 03/045920 (2003-06-01), None
patent: WO 03/070244 (2003-08-01), None
patent: WO 03/087044 (2003-10-01), None
patent: WO 03/087045 (2003-10-01), None
patent: WO 03/087046 (2003-10-01), None
patent: WO 03/097047 (2003-11-01), None
patent: WO2004/004714 (2004-01-01), None
patent: WO 2004/004714 (2004-01-01), None
patent: WO 2004/028459 (2004-04-01), None
patent: WO 2004/043958 (2004-05-01), None
RN 1026906-40-0 Registry (2008).
Roufos et al., J. Med. Chem., (1996), vol. 39(7), pp. 1514-1520, “A structure—Activity relationship study of novel phenylacetamides which are sodium channel blockers”.
Dyke et al., Exp. Opin. Ther. Patents (2005), vol. 15, pp. 1303-1313, “Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity—an update”.
Kowalski et al., Exp. Opin. Ther. Patents (2004), vol. 13, pp. 1113-1122, “Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity”.
Clark et al., J. Med. Chem., (2004), vol. 47, pp. 3962-3971, “A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor”.
Arienzo et al., Bioorg. & Medicinal Chem. Letters, (2004), vol. 14, pp. 4099-4102, “Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists”.
Mohammad R. Marzabadi et al., U.S. Appl. No. 10/189,146 filed Jul. 3, 2002.
Patane, M. A. et al., “Phenylacetamides as Selective Alpha-1A Adreergic Receptor Antagonists”, Bioorgainc & Medicinal Chemistry Letters, 2000, pp. 1621-1624, vol. 10.
Fukami Takehiro
Ishikawa Makoto
Kanatani Akio
Moriya Minoru
Sakamoto Toshihiro
Banyu Pharmaceutical Co. Ltd.
Chang Celia
Fair Janet E.
Todaro John C.
LandOfFree
Melanin-concentrating hormone receptor antagonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanin-concentrating hormone receptor antagonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanin-concentrating hormone receptor antagonists... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241996